|
Status |
Public on Dec 01, 2012 |
Title |
DAPT rep1 |
Sample type |
RNA |
|
|
Source name |
DAPT rep1
|
Organism |
Homo sapiens |
Characteristics |
cell type: human lung cancer cell line mutated in KRAS cell line: NSCLC H358 treatment: DAPT
|
Treatment protocol |
Cells were treated with the gamma-secretase inhibitor DAPT
|
Growth protocol |
10% FCS in DMEM
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was extracted with Trizol and then purified with Rneasy Micro kit
|
Label |
Cy3
|
Label protocol |
Standard
|
|
|
Hybridization protocol |
Standard
|
Scan protocol |
Standard
|
Description |
human lung cancer cell line mutated in KRAS
|
Data processing |
Background correction was carried out using normexp, data was normalized using quantiles between-arrays normalization. Data processing was carried out using Bioconductor´s limma package.
|
|
|
Submission date |
May 18, 2012 |
Last update date |
Dec 01, 2012 |
Contact name |
Antonio Maraver |
E-mail(s) |
amaraver@cnio.es
|
Organization name |
Centro Nacional de Investigaciones Oncológicas
|
Department |
Molecular Oncology
|
Lab |
Tumor Supression Group
|
Street address |
Calle Melchor Fernandez Almagro 3
|
City |
Madrid |
State/province |
Madrid |
ZIP/Postal code |
28029 |
Country |
Spain |
|
|
Platform ID |
GPL14550 |
Series (1) |
GSE38054 |
Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma through derepression of DUSP1 phosphatase and inhibition of ERK |
|